Shock is a life-threatening condition caused by inadequate tissue perfusion and oxygen delivery. Early recognition and treatment is important to prevent progression. The main goals in treating shock are to restore oxygen delivery through fluid resuscitation and addressing the underlying cause. Fluid therapy aims to optimize cardiac output and tissue perfusion, but treating the cause of shock such as hemorrhage, sepsis, or heart failure is also critical for patient survival.
anatomy of the lower extremity veins, CVI , ambulatory venous hypertension, varicose veins , clinical examination and performance of various tests of the varicose veins
anatomy of the lower extremity veins, CVI , ambulatory venous hypertension, varicose veins , clinical examination and performance of various tests of the varicose veins
G I bleeding with radiological interventions(ACR Appropriateness Criteria).Tc-99m RBC scintigraphy,Catheter-directed Angiography,Pharmacological control,Embolization,Arterial interventions,Endoscopy,CT Angiography
G I bleeding with radiological interventions(ACR Appropriateness Criteria).Tc-99m RBC scintigraphy,Catheter-directed Angiography,Pharmacological control,Embolization,Arterial interventions,Endoscopy,CT Angiography
A presentation by Dr Dave Collins of SASH Vets Sydney
on Canine Biliary Disease - Gallbladder mucocoeles, Cholangitis and Extrahepatic bile duct obstruction.
SASH : Intravenous Lipid Emulsion - Applications in Toxicology by Dr Nicole ...SASH Vets
A presentation by Dr Nicole Spurlock
Emergency and Critical Care Medicine Vet at SASH veterinary hospital in Sydney Australia on Intravenous Lipid Emulsion and its Applications in Toxicology
SHOCK SYNDROMESHOCK SYNDROME
• Shock is a condition in which the cardiovascular system
fails to perfuse tissues adequately
• An impaired cardiac pump, circulatory system, and/or
volume can lead to compromised blood flow to tissues
• Inadequate tissue perfusion can result in:
– generalized cellular hypoxia (starvation)
– widespread impairment of cellular metabolism
– tissue damage organ failure
– death
ATHOPHYSIOLOGYPATHOPHYSIOLOGY
Cells switch from aerobic to anaerobic metabolism
lactic acid production
Cell function ceases & swells
membrane becomes more permeable
electrolytes & fluids seep in & out of cell
Na+/K+ pump impaired
mitochondria damage
cell death
Shock: A review of hypovolemic, septic, cardiogenic and neurogenic shock.Joseph A. Di Como MD
A review of different types of shock encountered in patients. Hypovolemic, septic, cardiogenic and neurogenic shock. We review etiology, pathophysiology, diagnosis, treatment and how to differentiate between them.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
5. WHAT’S BAD ABOUT
SHOCK?
• Preferential shunting of blood away from splanchnic
circulation, skin and muscle
• GI translocation sepsis
• Sluggish blood flow through capillary beds
• renal
• cerebral
• myocardial
• Further anaerobic metabolism
• cellular energy deficit MOF
6. OXYGEN DELIVERY (DO2)
DO2 = CO x CaO2
HR x SV (Hgb x 1.36 x SaO2) + (0.0031 x PaO2)
EDV - ESV
venous return and diastolic function
systolic function and SVR
blood volume and SVR
9. DO2 = CO x CaO2
HR x SV (Hgb x 1.36 x SaO2) + (0.0031 x PaO2)
EDV - ESV
venous return and diastolic function
systolic function and SVR
blood volume and SVR
10. CAUSES OF
HYPOVOLAEMIC SHOCK
• Haemorrhage
• disruption of vessels
• trauma
• neoplasia
• coagulopathy
• Severe dehydration leading to hypovolaemia
• prolonged v/d
• massive polyuria
• burns
• third spacing
• inadequate access to water
11. DEHYDRATION ≠ HYPOVOLAEMIA
• Dehydration is a decrease in extracellular fluid volume, i.e-
the interstitial and intravascular spaces
• Because blood volume is spared at the expense of
interstitial volume, “hydration” generally refers the
interstitial fluid volume
• Dehydrated patients may or may not be hypovolaemic
• Hypovolaemic patients may or may not be dehydrated
12. HYDRATION
• MM moistness
• Skin turgor
• Globe position
VOLUME
• Heart rate
• MM colour, CRT
• Pulse quality
• Temperature
14. MALDISTRIBUTIVE SHOCK
• Maldistribution is a loss of vascular tone (SVR)
• Leads to sluggish blood flow and DO2, particularly in
capillaries, and decreased venous return, with knock-on
effects for cardiac output
15. DO2 = CO x CaO2
HR x SV (Hgb x 1.36 x SaO2) + (0.0031 x PaO2)
EDV - ESV
venous return and diastolic function
systolic function and SVR
blood volume and SVR
17. SEPSIS
The pathogenesis of maldistributive shock in sepsis is multi-
factorial:
• increased production of nitric oxide
• over-activation of K+/ATP channels
• deficiency of vasopressin
• critical illness-related corticosteroid insufficiency
18. CARDIOGENIC SHOCK
Shock related to failure of the pump mechanism of the heart
• failure to fill during diastole
• failure to eject adequate stroke volume during systole
CHF adds hypoxia to the mix
19. DO2 = CO x CaO2
HR x SV (Hgb x 1.36 x SaO2) + (0.0031 x PaO2)
EDV - ESV
venous return and diastolic function
systolic function and SVR
blood volume and SVR
22. METABOLIC SHOCK
• Deranged intracellular metabolic activity
• DO2 is normal
• Examples:
• hypoglycaemia
• toxicities that cause uncoupling of ox phos:
• cyanide
• arsenic
• 1080
• bromethalin
• mitochondrial dysfunction in sepsis and SIRS
23. HYPOXIC SHOCK
• Decrease in arterial blood oxygen content
• i.e- not related to blood flow
• Examples:
• severe anaemia (PCV < 10%)
• CO toxicity
• methaemoglobinaemia
• severe pulmonary disease
24.
25. IDENTIFYING SHOCK
Mixture of history, physical exam and laboratory evidence
Physical exam is your most important tool
26. IDENTIFYING SHOCK
Perfusion parameters:
• MM colour*
• CRT
• HR
• pulse quality
• temperature (particularly of extremities)
• mentation
• urine output
• blood pressure
* may be injected with maldistribution
27. LABORATORY
EVIDENCE OF SHOCK
Less fancy:
• metabolic acidosis
• decreased SBE
• decreased HCO3
• +/- acidaemia (depends on compensation)
• hyperlactataemia
• pre-renal azotaemia
• oliguria/anuria
• estimate volume status and CO via echocardiography
28. LACTATE
• Produced from pyruvate, a waste product of glycolysis
• During anaerobic metabolism, there is increased
production of pyruvate increased lactate production
• The most common cause of hyperlactataemia is anaerobic
metabolism during shock (“Type A hyperlactataemia”)
• Production also increases with SIRS/sepsis,
administration of steroids and some types of neoplasia
(“Type B hyperlactataemia”)
29. LABORATORY
EVIDENCE OF SHOCK
Fancy:
• direct CO monitoring via PAC (gold standard)
• mixed venous oxygen via PAC
• combined CVP and direct BP
• central venous oxygen via CVC
31. COMPENSATED SHOCK
• Catecholamine surge to maintain perfusion/DO2 causes
tachycardia and vasoconstriction
• Can be hard to identify; tachycardia in a patient that’s not
boisterous or stressed
32. • HR 130 - 160
• tall, narrow pulses
• pink/pale pink MM (+/- “injected” in sepsis/SIRS)
• CRT 0.5 – 1.5 sec
• normal body temperature (+/- elevated in sepsis/SIRS)
• extremities may be cool
• quiet mentation
• normal BP
• normal UOP
• normal mild hyperlactataemia
37. • HR >200
• ** bradycardia may develop shortly before death.
• weak to absent femoral pulses
• grey/patchy MM
• CRT > 2 sec or undetectable
• hypothermia and cold extremities
• obtundation
• severe hypotension
• decreased absent urine output
• severe hyperlactataemia
38. CATS ARE NOT SMALL DOGS
• Cats tend to become bradycardic and hypothermic earlier
in shock, particularly in sepsis
• A sick bradycardic cat is a very sick cat indeed
39. TREATING SHOCK
DO2 = CO x CaO2
HR x SV (Hgb x 1.36 x SaO2) + (0.0031 x PaO2)
EDV - ESV
venous return and diastolic function
systolic function and SVR
blood volume and SVR
40. FLUID THERAPY IN
SHOCK
• Fluid “resusc” is usually performed with isotonic
crystalloids
• Shock dose:
• 90ml/kg in dogs
• 60ml/kg cats
• How do we give it?
• Fast!
respective blood volumes
41. • Administer ¼ shock dose over 10 – 15 min then re-assess
your patient.
• If your goals of resusc have not been met, keep going
• Goals of resusc:
• HR 80 – 120
• pink MM, CRT 1 – 2 s
• normal pulse quality
• warm extremities, normothermia
• normal mentation
• SBP 100 – 140
• normal UOP
FAST?
44. OTHER FLUID TYPES
• Hypertonic saline (7%)
• hypertonic crystalloid
• dose: 3 – 5ml/kg once
• Artificial colloids
• use in shock is controversial
• renal failure, coagulopathies
• NEVER bolus hypotonic fluids
• 0.45% saline
• 0.45% saline + 2.5% glucose
• 5% glucose in water
• plasmalyte-56
• normosol-M
45. I’VE GIVEN SHOCK FLUIDS …
NOW WHAT?
• In cases of uncomplicated hypovolaemia, your work is
done
• In most cases, shock will continue unless you address the
the underlying cause, because only 25% of your
crystalloids will still be in IV space 30 min after infusion
• Must diagnose and address the underlying cause ASAP
46. • Sepsis
• volume first
• vasopressors if needed, once resusc
• treat the septic focus
• Active haemorrhage
• need to stop the haemorrhage
• large amounts of fluids can exacerbate bleeding
• patients may benefit from a low-volume resusc strategy
until haemostasis can be achieved
• blood products early
47. • GDV
• hypovolaemia plays a role
• need to also relieve the obstruction
• Concurrent shock and head trauma
• treat the CV system first!
• essential for adequate cerebral DO2
• once perfusion is restored, administer hyperosmolar
agents
48. OTHER TYPES OF
SHOCK
• Cardiogenic shock
• NO FLUIDS
• pulmonary oedema
• oxygen, furosemide
• nitroprusside
• pleural effusion
• thoracocentesis
• dobutamine/pimobendan for systolic failure
• anti-arrhythmics for tachycardias
• pacemaker for bradycardias
• pericardial effusion
• pericardiocentesis STAT!
• Severe anaemia
• red cells!
• usually pRBC